Accès ouvert
2025
article
OpenAlex
Elena Zamorano-Domínguez, Lucía Morales-Cacho, Rafael Barrero, Silvia Jiménez-Parrado et autres
The KRAS oncogene has been associated with many types of cancer, including pancreatic, lung, and colorectal. For decades, its gene products were thought to be undruggable. However, during the last decade, a large battery of KRAS inhibitors selective against specific mutations (KRAS …
es, us, ch, cu, ar
(code pays fourni par la source)
Accès ouvert
2010
article
OpenAlex
Matthias Drosten, Alma Dhawahir, Eleanor Y. M. Sum, Jelena Urosevic et autres
es
(code pays fourni par la source)
2009
article
OpenAlex
Jelena Urosevic, Eleanor Y. M. Sum, Victoria Moneo, Matthias Drosten et autres
Mutational activation of RAS proteins occurs in nearly 30% of all human tumors. To date direct pharmacological inhibition of RAS oncoproteins has not been possible. As a consequence, current strategies are focusing on the development of inhibitors that target those kinases acting …
es
(code pays fourni par la source)
Accès ouvert
2003
article
OpenAlex
Carmen E. Guerra, Nieves Mijimolle, Alma Dhawahir, Pierre R. Dubus et autres
es, fr
(code pays fourni par la source)